Dr Helen Roberts
@drhelenroberts.bsky.social
Associate Professor in Skeletal Cancer Research, Co-Director of the Centre for Investigative and Diagnostic Oncology, Director of Programmes at Middlesex University
Reposted by Dr Helen Roberts
📋 Importance: LGK974 therapy would likely be an option for treating disease early in children. This would potentially avoid risky surgical treatments such as skull decompression surgery.
April 22, 2025 at 5:21 PM
📋 Importance: LGK974 therapy would likely be an option for treating disease early in children. This would potentially avoid risky surgical treatments such as skull decompression surgery.
Reposted by Dr Helen Roberts
💡A huge shout out to all of the authors of this study Tim Dreyer, Jacob Keen, Leah Wells, Mark Hopkinson, Isabel Orriss, Gill Holdsworth and Andy Pitsillides - you are all great! Also many thanks to our funders UCB Pharma for your continued support.
April 22, 2025 at 5:22 PM
💡A huge shout out to all of the authors of this study Tim Dreyer, Jacob Keen, Leah Wells, Mark Hopkinson, Isabel Orriss, Gill Holdsworth and Andy Pitsillides - you are all great! Also many thanks to our funders UCB Pharma for your continued support.
Reposted by Dr Helen Roberts
💊 What We Found: A drug called LGK974 reduced skull and ear bone mass of young mice with sclerosteosis disease, indicating that it effectively limits skeletal overgrowth at sites with severe/fatal pathology.
April 22, 2025 at 5:20 PM
💊 What We Found: A drug called LGK974 reduced skull and ear bone mass of young mice with sclerosteosis disease, indicating that it effectively limits skeletal overgrowth at sites with severe/fatal pathology.